Order Samples

How Florastor® Protects & Restores Against Antibiotics

Recommend Florastor Probiotic During & After Antibiotic Therapy

Based on a review of clinical and pre-clinical studies:

  • During antibiotic therapy, Florastor significantly slows the decline of healthy gut flora.
  • After antibiotic therapy, Florastor speeds up the restoration of healthy gut flora.
Florastor protects and restores essential gut bacteria
During a 2-week ATB therapy, the healthy gut flora suffers an abrupt decline (A). Florastor administered during ATB therapy, can slow this decline by protecting the gut flora (B). If Florastor is administered following ATB therapy, Florastor can speed up the restoration of essential bacteria (C). Therefore, the ideal is treatment with Florastor during and following ATB treatment (D). This is represented by the hypothetical dotted line which was derived from the other lines12.

Learn How Florastor Reduces the Risk of Antibiotic-Associated Diarrhea

Read More

Benefits of Florastor

Florastor Safety Warning:

Do not use Florastor or other probiotics in any ICU setting and in those individuals with open arterial and venous access required (such as a Vascath, Permcath, or AV fistula).

Do not use for any individual with a central line or port or in the surroundings of any patient with a central line or port. [Central lines include short- and long-term central venous catheters (CVCs) and peripherally inserted central catheters (PICCs)]

Do not use Florastor for pre- or post- organ or bone marrow transplant patients and other patients considered severely immunocompromised or critically ill.

Do not use Florastor probiotics if allergic to any components (especially yeast).

Very rarely, side effects such as: allergic reaction (skin rash). Fungemia or sepsis in patients with a central venous catheter, and in hospitalized, immunocompromised patients may occur.

For product questions or to report an adverse event, please call (877) 356-7787.

See References
  1. Kabbani TA, Pallav K, Dowd SE, Villafuerte-Galvez J, Vanga RR, Castillo NE, Hansen J, Dennis M, Leffler DA, Kelly CP. Prospective randomized controlled study on the effects of Saccharomyces boulardii CNCM I-745 and amoxicillin-clavulanate or the combination on the gut microbiota of healthy volunteers. Gut Microbes. 2017 Jan 2;8(1):17-32. doi: 10.1080/19490976.2016.1267890. Epub 2016 Dec 14. PMID: 27973989; PMCID: PMC5341914.
  2. Martins FS, Silva AA, Vieira AT, Barbosa FH, Arantes RM, Teixeira MM, Nicoli JR. Comparative study of Bifidobacterium animalis, Escherichia coli, Lactobacillus casei and Saccharomyces boulardii probiotic properties. Arch Microbiol. 2009 Aug;191(8):623-30. doi: 10.1007/s00203-009-0491-x. Epub 2009 Jun 13. PMID: 19526225.
  3. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol. 2006 Apr;101(4):812-22. doi: 10.1111/j.1572-0241.2006.00465.x. PMID: 16635227.
  4. C, Mahieux S, Dubreuil LJ., Neut C. Antibiotic susceptibility of probiotic strains: Is it reasonable to combine probiotics with antibiotics? Med Mal Infect. 2017 Nov;47(7):477-483. doi: 10.1016/j.medmal.2017.07.001. Epub 2017 Aug 7. PMID: 28797834.
  5. Shan LS et al. Prevention and treatment of diarrhoea with Saccharomyces boulardii in children with lower respiratory tract infections. Beneficial Microbes. 2013;4(4):329-334. doi:10.3920/BM2013.0008.
  6. Surawicz CM, McFarland LV, Greenberg RN, Rubin M, Fekety R, Mulligan ME, Garcia RJ, Brandmarker S, Bowen K, Borjal D, Elmer GW. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000 Oct;31(4):1012-7. doi: 10.1086/318130. Epub 2000 Oct 25. PMID: 11049785.
  7. Szajewska H, Kołodziej M. Systematic review with meta-analysis: Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea. Aliment Pharmacol Ther. 2015 Oct;42(7):793-801. doi: 10.1111/apt.13344. Epub 2015 Jul 27. PMID: 26216624.
  8. Szajewska H, Kołodziej M, Zalewski BM. Systematic review with meta-analysis: Saccharomyces boulardii for treating acute gastroenteritis in children-a 2020 update. Aliment Pharmacol Ther. 2020 Apr;51(7):678-688. doi: 10.1111/apt.15659. Epub 2020 Feb 13. PMID: 32056266.
  9. Swidsinski A, Loening-Baucke V, Verstraelen H, Osowska S, Doerffel Y. Biostructure of fecal microbiota in healthy subjects and patients with chronic idiopathic diarrhea. Gastroenterology. 2008 Aug;135(2):568-79. doi: 10.1053/j.gastro.2008.04.017. Epub 2008 Apr 18. PMID: 18570896.
  10. Zhou BG, Chen LX, Li B, Wan LY, Ai YW. Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis. Helicobacter. 2019 Oct;24(5):e12651. doi: 10.1111/hel.12651. Epub 2019 Aug 14. PMID: 31414551.
  11. Can M et al. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: A prospective study. Medical Science Monitor. 2006;12(4):2004-2007.
  12. More MI, Swidsinski A. Saccharomyces boulardii CNCM I-745 supports regeneration of the intestinal microbiota after diarrheic dysbiosis - A review. Clinical and Experimental Gastroenterology. 2015;8:237-255. doi:10.2147/CEG.S85574.
  13. Seddik H et al. Saccharomyces boulardii CNCM I-745® plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial. European Journal of Clinical Pharmacology. 2019;75(5):639-645. doi:10.1007/s00228-019-02625-0.
  14. McFarland, L. V. (2008). Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol. 3, 563-578. doi: 10.2217/17460913.3.5.563
  15. Beaugerie, L., Flahault, A., Barbut, F., Atlan, P., Lalande, V., Cousin, P., et al. (2003). Antibiotic-associated diarrhoea and Clostridium difficile in the community. Aliment Pharmacol. Ther. 17,905-912. doi:10.1046/j. 1365-2036.2003.01531.x
  16. Buts, J.P., Bernasconi, P., Van Craynest, M.P., Maldague, P., & De Meyer, R. (1986). Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatric Research, 20, 192-196.
  17. Czerucka D, Rampal P. Diversity of Saccharomyces boulardii CNCM I-745 mechanisms of action against intestinal infections. World journal of gastroenterology. 2019;25(18):2188-2203. doi:10.3748/wjg.v25.i18.2188.
  18. Joly F et al. Saccharomyces boulardii CNCM I-745. In: Marteau P, Dore J, eds. Gut Microbiota: A Full-Fledged Organ. Paris: John Libbey Eurotext; 2017:305-350.
Welcome to the Florastor® site for Healthcare Professionals

Are you a health care professional?

No

By indicating that I am a Health Care Professional, I acknowledge: